Sotera Health Company Common Stock

SHCNasdaqCIK 1822479Healthcare / Healthcare Providers & Servicesfiscal year ends December27 quarters since 2020

Revenue, Q3 FY2026
$325M
+4.4% on Q3 FY2025
Net income
$58M
+20.6% on Q3 FY2025
Free cash flow
$58M
+65.0% on Q3 FY2025
Diluted EPS
$0.20
+17.6% on Q3 FY2025
Revenue, TTM
$1.2B
trailing four quarters
Net margin, TTM
14.1%
net income $173M
Free cash flow, TTM
$135M
$332M less $196M capex
Cash and equivalents
$412M
long-term debt $2.1B, Sep 30, 2026
Shares, 12-month change
+0.5%
286M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$4.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Sotera Health Company Common Stock reported revenue of $325M, +4.4% on Q3 FY2025, and net income of $58M (+20.6%). Free cash flow, operating cash flow less capital expenditures, was $58M ($111M less $53M). Diluted earnings per share were $0.20.

Share price

Daily candlesticks from November 18, 2024 to November 13, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

SHC daily priceSplit-adjusted, US dollars; an earnings release
Nov 13, 2026O $16.39 · H $16.65 · L $16.15 · C $16.61 · +1.90% on the dayOver the range: +3.75%, Nov 14, 2025 to Nov 13, 2026
$13$15$16$18$20Nov 25Jan 26Apr 26Jun 26Sep 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 3, 2026.

Revenue and net incomeRevenueNet income
−$400M−$200M$0$200M$400MQ4'22, Revenue: $252MQ4'22, Net income: −$320MQ4'22Q1'23, Revenue: $221MQ1'23Q2'23, Revenue: $255MQ2'23, Net income: $24MQ2'23Q3'23, Revenue: $263MQ3'23, Net income: −$14MQ3'23Q4'23, Revenue: $310MQ4'23, Net income: $39MQ4'23Q1'24, Revenue: $248MQ1'24Q2'24, Revenue: $277MQ2'24, Net income: $9MQ2'24Q3'24, Revenue: $285MQ3'24, Net income: $17MQ3'24Q4'24, Revenue: $290MQ4'24, Net income: $12MQ4'24Q1'25, Revenue: $255MQ1'25, Net income: −$13MQ1'25Q2'25, Revenue: $294MQ2'25, Net income: $8MQ2'25Q3'25, Revenue: $311MQ3'25, Net income: $48MQ3'25Q4'25, Revenue: $303MQ4'25, Net income: $35MQ4'25Q1'26, Revenue: $280MQ1'26, Net income: $27MQ1'26Q2'26, Revenue: $321MQ2'26, Net income: $54MQ2'26Q3'26, Revenue: $325MQ3'26, Net income: $58MQ3'26−$400M−$200M$0$200M$400MQ4'22, Revenue: $252MQ4'22, Net income: −$320MQ4'22Q1'23, Revenue: $221MQ1'23Q2'23, Revenue: $255MQ2'23, Net income: $24MQ2'23Q3'23, Revenue: $263MQ3'23, Net income: −$14MQ3'23Q4'23, Revenue: $310MQ4'23, Net income: $39MQ4'23Q1'24, Revenue: $248MQ1'24Q2'24, Revenue: $277MQ2'24, Net income: $9MQ2'24Q3'24, Revenue: $285MQ3'24, Net income: $17MQ3'24Q4'24, Revenue: $290MQ4'24, Net income: $12MQ4'24Q1'25, Revenue: $255MQ1'25, Net income: −$13MQ1'25Q2'25, Revenue: $294MQ2'25, Net income: $8MQ2'25Q3'25, Revenue: $311MQ3'25, Net income: $48MQ3'25Q4'25, Revenue: $303MQ4'25, Net income: $35MQ4'25Q1'26, Revenue: $280MQ1'26, Net income: $27MQ1'26Q2'26, Revenue: $321MQ2'26, Net income: $54MQ2'26Q3'26, Revenue: $325MQ3'26, Net income: $58MQ3'26−$400M−$200M$0$200M$400MQ4'22, Revenue: $252MQ4'22, Net income: −$320MQ1'23, Revenue: $221MQ1'23Q2'23, Revenue: $255MQ2'23, Net income: $24MQ3'23, Revenue: $263MQ3'23, Net income: −$14MQ3'23Q4'23, Revenue: $310MQ4'23, Net income: $39MQ1'24, Revenue: $248MQ1'24Q2'24, Revenue: $277MQ2'24, Net income: $9MQ3'24, Revenue: $285MQ3'24, Net income: $17MQ3'24Q4'24, Revenue: $290MQ4'24, Net income: $12MQ1'25, Revenue: $255MQ1'25, Net income: −$13MQ1'25Q2'25, Revenue: $294MQ2'25, Net income: $8MQ3'25, Revenue: $311MQ3'25, Net income: $48MQ3'25Q4'25, Revenue: $303MQ4'25, Net income: $35MQ1'26, Revenue: $280MQ1'26, Net income: $27MQ1'26Q2'26, Revenue: $321MQ2'26, Net income: $54MQ3'26, Revenue: $325MQ3'26, Net income: $58MQ3'26

Net income losses drawn in red.

Free cash flow
−$400M−$200M$0$200MQ4'22, Free cash flow: $30MQ4'22Q1'23, Free cash flow: −$11MQ1'23Q2'23, Free cash flow: −$390MQ2'23Q3'23, Free cash flow: −$10MQ3'23Q4'23, Free cash flow: $48MQ4'23Q1'24, Free cash flow: −$25MQ1'24Q2'24, Free cash flow: $19MQ2'24Q3'24, Free cash flow: $61MQ3'24Q4'24, Free cash flow: −$10MQ4'24Q1'25, Free cash flow: $36MQ1'25Q2'25, Free cash flow: $26MQ2'25Q3'25, Free cash flow: $35MQ3'25Q4'25, Free cash flow: $52MQ4'25Q1'26, Free cash flow: −$17MQ1'26Q2'26, Free cash flow: $42MQ2'26Q3'26, Free cash flow: $58MQ3'26−$400M−$200M$0$200MQ4'22, Free cash flow: $30MQ4'22Q1'23, Free cash flow: −$11MQ1'23Q2'23, Free cash flow: −$390MQ2'23Q3'23, Free cash flow: −$10MQ3'23Q4'23, Free cash flow: $48MQ4'23Q1'24, Free cash flow: −$25MQ1'24Q2'24, Free cash flow: $19MQ2'24Q3'24, Free cash flow: $61MQ3'24Q4'24, Free cash flow: −$10MQ4'24Q1'25, Free cash flow: $36MQ1'25Q2'25, Free cash flow: $26MQ2'25Q3'25, Free cash flow: $35MQ3'25Q4'25, Free cash flow: $52MQ4'25Q1'26, Free cash flow: −$17MQ1'26Q2'26, Free cash flow: $42MQ2'26Q3'26, Free cash flow: $58MQ3'26−$400M−$200M$0$200MQ4'22, Free cash flow: $30MQ1'23, Free cash flow: −$11MQ1'23Q2'23, Free cash flow: −$390MQ3'23, Free cash flow: −$10MQ3'23Q4'23, Free cash flow: $48MQ1'24, Free cash flow: −$25MQ1'24Q2'24, Free cash flow: $19MQ3'24, Free cash flow: $61MQ3'24Q4'24, Free cash flow: −$10MQ1'25, Free cash flow: $36MQ1'25Q2'25, Free cash flow: $26MQ3'25, Free cash flow: $35MQ3'25Q4'25, Free cash flow: $52MQ1'26, Free cash flow: −$17MQ1'26Q2'26, Free cash flow: $42MQ3'26, Free cash flow: $58MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3BQ4'22, Cash and equivalents: $395MQ4'22, Long-term debt: $1.7BQ4'22Q1'23, Cash and equivalents: $648MQ1'23, Long-term debt: $2.2BQ1'23Q2'23, Cash and equivalents: $263MQ2'23, Long-term debt: $2.2BQ2'23Q3'23, Cash and equivalents: $245MQ3'23, Long-term debt: $2.2BQ3'23Q4'23, Cash and equivalents: $296MQ4'23, Long-term debt: $2.2BQ4'23Q1'24, Cash and equivalents: $261MQ1'24, Long-term debt: $2.2BQ1'24Q2'24, Cash and equivalents: $246MQ2'24, Long-term debt: $2.2BQ2'24Q3'24, Cash and equivalents: $307MQ3'24, Long-term debt: $2.2BQ3'24Q4'24, Cash and equivalents: $277MQ4'24, Long-term debt: $2.2BQ4'24Q1'25, Cash and equivalents: $304MQ1'25, Long-term debt: $2.2BQ1'25Q2'25, Cash and equivalents: $332MQ2'25, Long-term debt: $2.2BQ2'25Q3'25, Cash and equivalents: $299MQ3'25, Long-term debt: $2.1BQ3'25Q4'25, Cash and equivalents: $345MQ4'25, Long-term debt: $2.1BQ4'25Q1'26, Cash and equivalents: $314MQ1'26, Long-term debt: $2.1BQ1'26Q2'26, Cash and equivalents: $357MQ2'26, Long-term debt: $2.1BQ2'26Q3'26, Cash and equivalents: $412MQ3'26, Long-term debt: $2.1BQ3'26$0$1B$2B$3BQ4'22, Cash and equivalents: $395MQ4'22, Long-term debt: $1.7BQ4'22Q1'23, Cash and equivalents: $648MQ1'23, Long-term debt: $2.2BQ1'23Q2'23, Cash and equivalents: $263MQ2'23, Long-term debt: $2.2BQ2'23Q3'23, Cash and equivalents: $245MQ3'23, Long-term debt: $2.2BQ3'23Q4'23, Cash and equivalents: $296MQ4'23, Long-term debt: $2.2BQ4'23Q1'24, Cash and equivalents: $261MQ1'24, Long-term debt: $2.2BQ1'24Q2'24, Cash and equivalents: $246MQ2'24, Long-term debt: $2.2BQ2'24Q3'24, Cash and equivalents: $307MQ3'24, Long-term debt: $2.2BQ3'24Q4'24, Cash and equivalents: $277MQ4'24, Long-term debt: $2.2BQ4'24Q1'25, Cash and equivalents: $304MQ1'25, Long-term debt: $2.2BQ1'25Q2'25, Cash and equivalents: $332MQ2'25, Long-term debt: $2.2BQ2'25Q3'25, Cash and equivalents: $299MQ3'25, Long-term debt: $2.1BQ3'25Q4'25, Cash and equivalents: $345MQ4'25, Long-term debt: $2.1BQ4'25Q1'26, Cash and equivalents: $314MQ1'26, Long-term debt: $2.1BQ1'26Q2'26, Cash and equivalents: $357MQ2'26, Long-term debt: $2.1BQ2'26Q3'26, Cash and equivalents: $412MQ3'26, Long-term debt: $2.1BQ3'26$0$1B$2B$3BQ4'22, Cash and equivalents: $395MQ4'22, Long-term debt: $1.7BQ1'23, Cash and equivalents: $648MQ1'23, Long-term debt: $2.2BQ1'23Q2'23, Cash and equivalents: $263MQ2'23, Long-term debt: $2.2BQ3'23, Cash and equivalents: $245MQ3'23, Long-term debt: $2.2BQ3'23Q4'23, Cash and equivalents: $296MQ4'23, Long-term debt: $2.2BQ1'24, Cash and equivalents: $261MQ1'24, Long-term debt: $2.2BQ1'24Q2'24, Cash and equivalents: $246MQ2'24, Long-term debt: $2.2BQ3'24, Cash and equivalents: $307MQ3'24, Long-term debt: $2.2BQ3'24Q4'24, Cash and equivalents: $277MQ4'24, Long-term debt: $2.2BQ1'25, Cash and equivalents: $304MQ1'25, Long-term debt: $2.2BQ1'25Q2'25, Cash and equivalents: $332MQ2'25, Long-term debt: $2.2BQ3'25, Cash and equivalents: $299MQ3'25, Long-term debt: $2.1BQ3'25Q4'25, Cash and equivalents: $345MQ4'25, Long-term debt: $2.1BQ1'26, Cash and equivalents: $314MQ1'26, Long-term debt: $2.1BQ1'26Q2'26, Cash and equivalents: $357MQ2'26, Long-term debt: $2.1BQ3'26, Cash and equivalents: $412MQ3'26, Long-term debt: $2.1BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Sotera Health Company Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue325321280303311294255290+4.4%
Cost of revenue144143133138134128119126+7.7%
Gross profit181178147166178167135164+1.8%
Research and development—————————
Selling, general and administrative6468685863696362+1.3%
Operating income———————87—
Other income (expense)33120601+571.1%
Pretax income847843707319(15)45+14.8%
Income tax252416362511(2)33+3.3%
Net income58542735488(13)12+20.6%
Diluted EPS ($)0.200.190.09—0.170.03(0.05)—+17.6%
Diluted shares (millions)289288288—287286284——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Sotera Health Company Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents412357314345299332304277+37.8%
Short-term investments—————————
Total current assets701646586613578608555526+21.3%
Total assets3,3873,3073,2363,2633,1863,2173,0983,072+6.3%
Total current liabilities224231208250242246226191−7.7%
Long-term debt2,1232,1262,1242,1272,1292,2032,2052,208−0.3%
Total debt2,1372,1392,1382,1412,1432,2172,2202,223−0.3%
Total liabilities2,6542,6412,6132,6572,6362,7052,6832,667+0.7%
Stockholders’ equity733666623606550511414405+33.2%
Shares outstanding (millions)286285285284284284284283—

Positions at each period end. Long-term debt is the line the filer tags, with or without its current portion. Total debt is one definition across filers, built from filed lines: long-term debt with its current portion plus short-term borrowings, finance leases where the filer folds them into its debt line, operating leases never; it is blank where the tags do not add up to it. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Sotera Health Company Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 8, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 27, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow111882910371575656+55.4%
Capital expenditures5346465136312066+46.1%
Free cash flow (CFO − capex)5842(17)52352636(10)+65.0%
Depreciation and amortization3333313328354140+14.7%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Sotera Health Company Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed May 13, 2021FY2019ended Dec 31, 2019filed Mar 1, 2022
Revenue1,1641,1001,0491,004931818778
Cost of revenue518498472447413375383
Gross profit646602577557519444395
Research and development———————
Selling, general and administrative253243237246198179147
Operating income—298277248257206184
Other income (expense)95761597
Pretax income148114106(243)176(39)(1)
Income tax706955(10)59(1)20
Net income784451(234)117(39)(21)
Diluted EPS ($)0.270.160.18(0.83)0.41(0.16)(0.09)
Diluted shares (millions)286285283280279238232

Balance sheet

Sotera Health Company Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed May 13, 2021FY2019ended Dec 31, 2019filed Mar 1, 2022
Cash and equivalents345277296395107102—
Short-term investments———————
Total current assets613526557645346315—
Total assets3,2633,0723,1303,1182,7902,761—
Total current liabilities250191231792161141—
Long-term debt2,1272,2082,2241,7471,7441,825—
Total debt2,1412,2232,2281,9441,7441,825—
Total liabilities2,6572,6672,6872,7672,2032,307—
Stockholders’ equity606405444350586452—
Shares outstanding (millions)284283283282283——

Cash flow statement

Sotera Health Company Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 27, 2025FY2023ended Dec 31, 2023filed Feb 27, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Mar 1, 2022FY2020ended Dec 31, 2020filed May 13, 2021FY2019ended Dec 31, 2019filed Mar 1, 2022
Operating cash flow287224(148)278282121149
Capital expenditures1381792151821025457
Free cash flow (CFO − capex)14945(363)961796792
Depreciation and amortization95847764646367
Share repurchases———00340
Dividends paid————00691

Insider activity

Form 4 filings by officers, directors and 10% owners, November 16, 2024 to November 16, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$21M
2 sales by 1 insider; officers and directors $21M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$1.5B
15 sales by 9 insiders; officers and directors $1.5B

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Aug 17, 2026Petras Michael B. Jr.Executive Chairman, Directoropen-market sale294,515$18.50$5M397,912Aug 19, 2026
Aug 17, 2026Petras Michael B. Jr.Executive Chairman, Directoropen-market saleindirect850,000$18.50$16M4MAug 19, 2026
Aug 7, 2026Rutz Michael PPresident of Sterigenicsopen-market sale150,000$18.84$3M334,279Aug 11, 2026
Aug 5, 2026Lyons Jonathan M.Sr. Vice President, CFOtax withholding11,316$17.98$203K217,304Aug 7, 2026
May 26, 2026Shader AltonChief Executive Officer, Directoraward375,939$0.00—375,939May 27, 2026
May 26, 2026Shader AltonChief Executive Officer, Directoraward203,634$0.00—579,573May 27, 2026
May 22, 2026Klee Ann R.Directoraward14,970$0.00—140,926May 27, 2026
May 22, 2026Kyle Richard GDirectoraward14,970$0.00—14,970May 27, 2026
May 22, 2026Krause Kenneth D.Directoraward14,970$0.00—14,970May 27, 2026
May 22, 2026Cunningham Sean LaurenceDirectoraward14,970$0.00—95,751May 27, 2026
May 22, 2026Flynn KarenDirectoraward14,970$0.00—54,191May 27, 2026
May 22, 2026Neary JamesDirectoraward14,970$0.00—95,751May 27, 2026
May 22, 2026Petrella Vincent KDirectoraward14,970$0.00—95,751May 27, 2026
May 22, 2026Chen RuoxiDirectoraward14,970$0.00—95,751May 27, 2026
May 22, 2026Simon, ChristopherDirectoraward14,970$0.00—34,102May 27, 2026
May 22, 2026Wheadon David E.Directoraward14,970$0.00—89,882May 27, 2026
May 13, 2026Warburg Pincus & CO.+7 moreDirector, 10% owneropen-market saleindirect19M$15.17$290M0May 15, 2026
May 13, 2026Warburg Pincus & CO.+9 moreDirector, 10% owneropen-market saleindirect19M$15.17$290M0May 15, 2026
May 13, 2026Gtcr Investment XI LLC+4 moreDirector, 10% owneropen-market saleindirect13M$15.17$193M0May 15, 2026
Mar 31, 2026Dimitrief AlexanderFormer SVP, GC and Sec.tax withholding7,941$14.34$114K312,040Apr 2, 2026
Mar 6, 2026Warburg Pincus Partners GP LLC+7 moreDirector, 10% owneropen-market saleindirect15M$15.27not summed19MMar 10, 2026
Mar 6, 2026Warburg Pincus Partners II, L.P.+9 moreDirector, 10% owneropen-market saleindirect15M$15.27$229M19MMar 10, 2026
Mar 6, 2026Gtcr Co-Invest XI LP+4 moreDirector, 10% owneropen-market saleindirect10M$15.27$153M13MMar 10, 2026
Mar 2, 2026Petras Michael B. Jr.Chairman & CEO, Directortax withholding31,339$15.91$499K521,451Mar 4, 2026
Mar 2, 2026Petras Michael B. Jr.Chairman & CEO, Directortax withholding40,302$15.91$641K481,149Mar 4, 2026

Full insider history for Sotera Health Company Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held SHC in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded SHC by quarter.

FundManagerQuarterValueSharesWeightMove
Greenlight CapitalDavid EinhornQ2 2026$73M4M1.88%added +100.2%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
SOTERA HEALTH COMPANY, CIK 1822479 on EDGAR
Extract generated
November 16, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue: CostOfRevenue
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated November 16, 2026.

JSON file
/data/financials/SHC.json